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A B S T R A C T
The current study is concerned with the identification of lead molecules based on the bis-coumarin scaffold
having selective urease inhibitory and antiglycation activities. For that purpose, bis-coumarins (1-44) were
synthesized and structurally characterized by different spectroscopic techniques. Eight derivatives 4, 8-10, 14,
17, 34, and 40 demonstrated urease inhibition in the range of IC50= 4.4 ± 0.21–115.6 ± 2.13 μM, as com-
pared to standard thiourea (IC50= 21.3 ± 1.3 μM). Especially, compound 17 (IC50= 4.4 ± 0.21 μM) was
found to be five-fold more potent than the standard. Kinetic studies were also performed on compound 17 in
order to identify the mechanism of inhibition. Kinetic studies revealed that compound 17 is a competitive
inhibitor. Antiglycation activity was evaluated using glycation of bovine serum albumin by methylglyoxal in
vitro. Compounds 2, 11-13, 16, 17, 19–22, 35, 37, and 42 showed good to moderate antiglycation activities with
IC50 values of 333.63–919.72 μM, as compared to the standard rutin (IC50= 294.46 ± 1.5 μM). Results of both
assays showed that the compounds with urease inhibitory activity did not show any antiglycation potential, and
vice versa. Only compound 17 showed dual inhibition potential. All compounds were also evaluated for cyto-
toxicity. Compounds 17, 19, and 37 showed a weak toxicity towards 3 T3 mouse fibroblast cell line. All other
compounds were found to be non-cytotoxic. Urease inhibition is an approach to treat infections caused by
ureolytic bacteria whereas inhibition of glycation of proteins is a strategy to avoid late diabetic complications.
Therefore, these compounds may serve as leads for further research.
1. Introduction
Bis-coumarins are biologically active pharmacophores, initially
isolated from natural sources [1,2]. Several biological activities are
associated with bis-coumarins, such as α-glucosidase [3], urease [4],
nucleotide pyrophosphatases-1 [5], and DNA polymerase β-lyase in-
hibitory activities [6]. Bis-coumarins are also reported to possess an-
ticoagulant, and hemorrhagic properties [7]. However, there is still a
need to explore this class for a wide spectrum of pharmacological ac-
tivities.
Urease (amidohydrolase EC 3.5.1.5) is a metalloenzyme, contains
nickel in its active site. It catalyzes the hydrolysis of urea into carbon
dioxide and ammonia [8,9]. This enzyme synthesizes by numerous
plants, animals, bacteria, and other organisms [10]. Hyperactivity of
urease is harmful to human and animal health, as well as for the agri-
cultural sector. Urease is a key virulence in the pathogenesis of ur-
olithiasis, urinary catheter encrustation, pyelonephritis, hepatic coma,
and hepatic encephalopathy [11,12]. It also participates in the
pathologies caused by ureolytic bacteria Helicobacter pylori (HP). It fa-
cilitates bacteria to survive in stomach at acidic pH during initial co-
lonization. Therefore, it plays an important role in the pathologies of
ulcers (gastric and peptic), and cancer [13-16]. In the agriculture
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2. Results and discussion
2.1. Chemistry
Bis-coumarin derivatives 1–44 were synthesized by reacting 6-
fluoro-4-hydroxy, 4-hydroxy, and 6-chloro-4-hydroxy coumarins with a
variety of benzaldehydes in the presence of tetraethylammonium bro-
mide (TEAB) as a catalyst. Reactions were performed in distilled water
(Scheme 1) and checked periodically by TLC analysis. Precipitates of
products were obtained in good yields (Table 1). Compounds were
structurally identified by various spectroscopic analyses such as 1H- and
13C NMR as well as FAB-, ESI-, and HRESI-MS.
2.2. Characteristic spectral features of representative compound 21
Structure elucidation of a new compound 21 is presented here as an
example. 1H- and 13C NMR spectra of compound 21 were recorded in
DMSO-d6. Characteristic signal of methine proton resonated as a singlet
at δH 5.60, also confirmed the formation of the bis-coumarin scaffold.
Amongst the protons of coumarin nucleus, H-7 and H-7′ resonated at δH
7.53 as triplet, and showed ortho coupling (t, J7,6/7′,6′ = J7,8/
7′,8′ = 6.9 Hz) with adjacent protons, H-6/H-6′ and H-8/H-8′. Similarly,
H-6 and H-6′ appeared as a triplet at δH 7.26, and also showed ortho
coupling (t, J6,5/6′,5′ = J6,7/6′,7′ = 7.5 Hz) with neighbouring protons. H-
5 and H-5′ appeared as the most downfield signal at δH 7.82 with ortho
coupling (d, J5,6/5′,6′ = 6.3 Hz) with the adjacent H-6 and H-6′. H-8 and
H-8′ appeared at δH 7.27, ortho coupled (d, J8,7/8′,7′ = 8.1 Hz) with H-7
and H-7′. H-2′′ and H-6′′ of ring R2 resonated as a broad singlet at δH
7.12 (Fig. 2).
Total 16 signals of carbon (eleven methine and fourteen quarternary
carbons) appeared in 13C NMR broad-band decoupled spectrum
(DMSO-d6). Most downfield signal of C-2 and C-2′, which are the qua-
ternary carbons of lactone moiety, appeared at δC 167.2. Similarly,
other quaternary C-10/C-10′, and C-4/C-4′ resonated at δC 164.2 and
152.4 as the downfield signals due to the adjacent electronegative
oxygen atom. An upfield characteristic signal resonated at δC 35.0,
corresponding to the methine CH carbon.
The structure of compound 21 was further confirmed with the help
Fig. 1. Structural similarity between rutin and bis-coumarins 1–44 as a rationale of the current study.
sector, hyperactivity of urease leads to considerable economic and en-
vironmental damage by liberating aberrantly large quantities of am-
monia into the atmosphere, during the process of urea fertilization 
[17]. Therefore, it is important to develop strategies based on urease 
inhibition to solve the problems caused by urease producing bacteria.
Glycation is a non-enzymatic reaction in which reducing sugars non-
enzymatically bind with the amino terminal of proteins via a nucleo-
philic addition reaction, ultimately giving rise to advanced glycation 
end products (AGEs). Haemoglobin, serum albumin, collagen, elastin, 
and crystalline are common proteins that undergo glycation. Changes in 
their structures and functions lead to different abnormalities such as 
atherosclerosis, neuropathy, diabetic retinopathy, diabetic nephro-
pathy, etc. This process is cumulatively called glycation stress [18,19]. 
In this process, reactive intermediates such as methylglyoxal (MG) are 
more prone to bind with amino groups as compared to their carbohy-
drate precursors. Eighty percent (80%) of blood proteins is serum al-
bumin, which is more likely to be glycated [20]. As a result of complex 
rearrangements, substitution, and addition reactions of glycated pro-
teins, AGEs are produced in the body which change the functions of 
proteins, and accumulate with time in different tissues [21-23]. Many 
late diabetic complications, such as retinopathy, nephropathy, catar-
acts, atherosclerosis, and osteoporosis are due to the glycation of vital 
proteins, and accumulation of AGEs [24]. The inhibition of glycation 
process plays a pivotal role in the prevention of many late diabetic 
complications. Therefore, it is important to find inhibitors for glycation.
Bis-coumarins have not yet been reported for their antiglycation 
activity. Fig. 1 showed that chromone ring, a positional isomer of 
coumarin, is the main scaffold of rutin which encouraged us to evaluate 
the compounds 1–44 for their antiglycation activity. Furthermore, we 
have previously reported bis-coumarins for urease inhibitory activity 
[4]. New members of this series were thus evaluated to identify more 
potent urease inhibitors [Fig. 1]. In brief, forty-four derivatives were 
synthesized and evaluated for their urease inhibitory, and antiglycation 
activities. After knowing the selective potential of compounds, cyto-
toxicity was also checked. To the best of our knowledge, except com-
pounds 6, 14, 16, 17, 19, 20, 23–26, 28, and 30–32 [25-29], the rest of 
the compounds were identified as new.
of FAB (Neg.)-MS, ESI-MS, and HRESI-MS. FAB (Neg.)-MS of compound
21 displayed the peaks at m/z=584 [M-H]−1, 586 [M+2-H]−1 and
588 [M+4-H]−1 which indicated the presence of two bromine atoms.
Similarly, ESI-MS of compound 21 displayed the [M+H]+, [M
+2+H]+, and [M+4+H]+ at m/z 585, 587, and 589, respectively.
HR-(ESI)MS showed the [M+H]+ at m/z 584.9208, corresponding to
the formula C25H15Br2O7 Calcd (584.9184). The UV spectrum of com-
pound 21 showed absorption at 298 nm, characteristic of coumarin
moiety. The structure of new compound 21 was thus deduced un-
ambiguously.
2.3. Bioactivities in vitro
Forty-four bis-coumarin derivatives were evaluated for urease in-
hibitory, and antiglycation activities (Table 1). Eight compounds 4,
8–10, 14, 17, 34, and 40, showed a good to moderate urease inhibitory
activity in the range of IC50= 4.4 ± 0.21–115.6 ± 2.13 μM, as com-
pared to standard thiourea (IC50= 21.3 ± 1.3 μM). Whereas, com-
pounds 2, 11–13, 16, 17, 19, 20–22, 35, 37, and 42 demonstrated good
to moderate antiglycation activities in the range of
IC50= 333.63–919.72 μM, as compared to standard rutin
(IC50= 294.46 ± 1.5 μM). Bis-coumarins have never been reported
before for its antiglycation activity. It is worth mentioning that the
compounds showed selective activity in both assays. Bis-coumarins
which showed urease inhibitory activity did not give the antiglycation
potential, and vice versa. All compounds were also checked for their
cytotoxicity and largely found to be non-cytotoxic.
2.4. Structure-activity relationship (SAR)
All structural features of bis-coumarin derivatives such as coumarin
ring, substitutions on coumarin rings (R1), and aryl ring (R2) apparently
playing their role in the inhibitory activity, and variation in the activity
can be attributed to the different substitution pattern on coumarin, and
aryl rings (Fig. 3).
Results presented in Table 1 indicate that almost all compounds
selectively exhibited their potential in both assays, and found to be non-
toxic as well.
Bis-coumarins 1–44 were divided into three categories in order to
understand the structure-activity pattern. In category “A”, fluoro
groups are present at C-6 and C-6ꞌ of bis-coumarin i.e. 1–15. Category
“B” compounds 16–31 has no substitution on both coumarin rings, and
category “C” has chloro groups at C-6 and C-6ꞌ i.e. compounds 32–44.
In category “A”, non-cytotoxic compound 8
(IC50= 30.3 ± 1.01 μM) with 3′′ -benzyloxy and 4′′-methoxy sub-
stitutions showed comparable urease inhibitory activity with the stan-
dard thiourea (IC50= 21.3 ± 1.3 μM), and did not show any anti-
glycation potential. The good urease inhibitory activity of the
compound 8 could be due to π-π stacking of the benzyloxy group with
the active site of urease enzyme. Activity of compound 8 was compared
with the activity of non-cytotoxic compound 14
(IC50= 187.3 ± 1.75 μM) which has a bromo group instead of a ben-
zyloxy at C-3′′, showed six times less urease inhibitory activity. This
indicated the involvement of benzyloxy in the inhibitory activity.
Similarly, compound 14 did not show any antiglycation potential. It is
worth mentioning that both compounds 8 and 14 showed selective
activity towards the urease, as well as being non-cytotoxic. Other
compounds with different positional combination of methoxy and
bromo groups such as compounds 3, 5, and 15, did not show any urease
inhibitory and antiglycation activities. However, all three were found to
be non-cytotoxic. The activity of compound 3 can be compared with
compound 2 (IC50= 378.03 ± 0.75 μM) which has a fluoro group,
instead of a bromo at C-2′′, showed an antiglycation potential com-
parable to the standard rutin (IC50= 294.46 ± 1.5 μM). It showed that
fluoro group on aryl ring plays an important role in the antiglycation
activity (Fig. 4).
In the same category “A”, compounds with the halogen substitutions
(4, 9, and 10), and the compounds with combinations of halogen and
hydroxy groups (11 and 12), showed a good selectivity and non-cyto-
toxicity. For example, compound 4 (IC50= 87.0 ± 0.88 μM) with
2′′,4′′-dichloro substitutions showed a selective urease inhibitory ac-
tivity, and no antiglycation activity. The two chloro groups on aryl ring
might form some polar interactions with the active site of the urease
enzyme. Similarly, another compound 9 (IC50= 79.8 ± 1.01 μM) with
a 4′′-trifluoromethyl group, also showed urease inhibitory activity but
no antiglycation activity. This might be that trifluoromethyl group es-
tablish polar interaction with the active site of urease enzyme.
However, its positional isomer 10 (IC50= 193.7 ± 0.66 μM) with a 4′′-
trifluoromethyl group, showed two times lower activity. It showed that
C-3′′ substitution is not favourable for urease inhibition (Fig. 5).
Compounds with the combination of halogen and hydroxy, such as
11 (OH and F para to each other) and 12 (OH and Cl para to each other)
showed no urease inhibition, however, they did show antiglycation
activity. Similarly, compound 13 (IC50= 443.64 ± 0.57 μM) with
2′′,4′′-dihydroxy substitutions also showed antiglycation potential
(Fig. 6). Thus hydroxy group is apparently playing an important role in
the antiglycation activity. Phenolic OH known to have radical scaven-
ging activity through phenolic OH groups, along with other structural
features which may contribute to the inhibition of protein glycation.
Involvement of hydroxy groups in the antiglycation activity was fur-
ther deduced by examining antiglycation activity pattern of compounds 16
(IC50=351.85 ± 3.56 μM), 17 (IC50=374.45 ± 1.21 μM), and 20
(IC50=434.71 ± 2.73 μM) belong to category “B”. Compound 16
(IC50=351.85 ± 3.56 µM), having a 2,3-dihydroxy substitution, was
selectively active against glycation but no urease inhibitory activity. The
antiglycation activity of compound 16 can be compared with compound
20 (IC50=434.71 ± 2.73 µM) which has a 2,4-dihydroxy group, instead
of 2,3-dihydroxy, and showed lower antiglycation activity. This shows that
the positions of OH substitution also plays a role in the activity. However,
incorporation of one or more hydroxy group in compound 17
(IC50=374.45 ± 1.21 µM) enhanced the antiglycation potential to a
considerable level. In addition, compound 17 was found to be a potent
urease inhibitor, with five times more activity than the standard thiourea
(IC50=21.3 ± 1.3 μM). Interestingly, this is the only compound which
showed dual inhibitory activity against urease and glycation (Fig. 7).
Other compounds with the halogen substitutions such as compound
22 with 3′′,5′′-dichloro substitutions, showed an antiglycation activity
(IC50= 428.84 ± 2.44 µM) but no urease inhibitory activity.
Compounds having the combination of halogen (Cl and Br) with the
hydroxy group such as 19 and 21, did not display any urease inhibition,
however, both compounds 19 (IC50= 432.58 ± 0.76 µM) and 21
(IC50= 397.07 ± 2.21 µM) showed antiglycation activity (Fig. 8). All
Scheme 1. Synthesis of bis-coumarin deri-
vatives 1–44.
Compounds R2 Urease Inhibitory Activity Antiglycation Activity Cytotoxicity
IC50 ± SEMa IC50 ± SEMa IC50 ± SEMa
Category A (R1=F)
1 NAb NAb NTc
2 NAb 378.03 ± 0.75 >30
3 NAb NAb NTc
4 87.0 ± 0.88 NAb NTc
5 NAb NAb NTc
6 NAb NAb NTc
7 NAb NAb NTc
8 30.3 ± 1.01 NAb NTc
9 79.8 ± 1.01 NAb NTc
10 193.7 ± 0.66 NAb NTc
11 NAb 399.47 ± 1.88 >30
12 NAb 465.33 ± 1.99 >30
13 NAb 443.64 ± 0.57 >30
14 187.3 ± 1.75 NAb NTc
(continued on next page)
Table 1
In vitro urease inhibitory activity, antiglycation activity, and cytotoxicity of bis-coumarins (1–44).
Table 1 (continued)
Compounds R2 Urease Inhibitory Activity Antiglycation Activity Cytotoxicity
IC50 ± SEMa IC50 ± SEMa IC50 ± SEMa
15 NAb NAb NTc
Category B (R1=H)
16 NAb 351.85 ± 3.56 >30
17 4.4 ± 0.21 374.45 ± 1.21 18.70 ± 0.57
18 NAb NAb NTc
19 NAb 397.07 ± 2.21 >30
20 NAb 434.71 ± 2.73 19.42 ± 0.79
21 NAb 432.58 ± 0.76 >30
22 NAb 428.84 ± 2.44 >30
23 NAb NAb NTc
24 NAb NAb NTc
25 NAb NAb NTc
26 NAb NAb NTc
27 NAb NAb NTc
28 NAb NAb NTc
(continued on next page)
Table 1 (continued)
Compounds R2 Urease Inhibitory Activity Antiglycation Activity Cytotoxicity
IC50 ± SEMa IC50 ± SEMa IC50 ± SEMa
29 NAb NAb NTc
30 NAb NAb NTc
31 NAb NAb NTc
Category C (R1=Cl)
32 NAb NAb NTc
33 NAb NAb NTc
34 115.6 ± 2.13 NAb NTc
35 NAb 744.82 ± 5.64 >30
36 NAb NAb NTc
37 NAb 919.72 ± 1.98 21.11 ± 1.27
38 NAb NAb NTc
39 NAb NAb NTc
40 36.5 ± 1.37 NAb NTc
41 NAb NAb NTc
(continued on next page)
three compounds were found to be non-cytotoxic.
In category “C”, compound 40 (IC50= 36.5 ± 1.37 μM) having 3′′-
bromo-4′′-hydroxy substitutions, showed a urease inhibitory activity
comparable to standard thiourea (IC50= 21.3 ± 1.3 μM) and found
non-cytotoxic. The hydroxy group is apparently making the hydrogen
bonding interaction as well as the bromo group involved in some polar
interaction with the active site of the enzyme. Activity of compound 40
can be compared with analogs 44 and 35 which have additional
methoxy and bromo group, respectively, at 5′′-position of R2, a com-
plete loss of activity was observed. The inactivity of the compounds
might be due to the additional groups which create the steric hindrance
for the hydroxy group to bind with the enzyme active site. However,
compound 35 (IC50= 744.82 ± 5.64 µM) showed selective antiglyca-
tion activity and also found to be non-cytotoxic. Furthermore, non-cy-
totoxic compounds 42 (IC50= 333.63 ± 1.98 µM) and 37
(IC50= 919.72 ± 1.98 µM) showed a selective good to moderate an-
tiglycation activity. Compound 42 has a 3′′,5′′-dibromo-4′′-hydroxy
substitution while compound 37 is with 4′′-bromo-3′′,5′′-dimethoxy
substitutions at phenyl ring R2. It is worthy to note that compounds 35,
37, and 42, are 3′′,4′′,5′′-trisubstituted analogs which demonstrated the
selective antiglycation potential. Another compound 34
(IC50= 115.6 ± 2.13 μM) having a 3′′,4′′,5′′-trihydroxy group,
showed selective but weak urease inhibitory activity. Its activity com-
pared with the structurally similar and most potent compound 17
(IC50= 4.4 ± 0.21 μM). Compound 34 might have a conformation
which does not fit well into the active site of enzyme. Similarly, addi-
tional chloro groups at C-6 and C-6′ positions are not playing their role
in the activity (Fig. 9).
In brief, it was observed that all derivatives, except 17, were found
to be selective and non-cytotoxic. Our next goal is to place heterocycles
on bis-coumarin skeleton in order to see their effects on selectivity and
cytotoxicity.
3. Conclusion
Synthetic bis-coumarins 1–44 were evaluated for their urease in-
hibitory and antiglycation activities. Seven derivatives 4, 8–10, 14, 34,
and 40 showed selective urease inhibition, whereas, twelve analogs 2,
11–13, 16, 17, 19–22, 35, 37, and 42 demonstrated antiglycation po-
tential. Only compound 17 showed dual inhibition. All compounds
were largely found to be non-cytotoxic. Newly identified compounds,
based on bis-coumarin scaffold, may serve as leads for future research
for more powerful, non-cytotoxic, and selective agents against urease
and protein glycation.
Table 1 (continued)
Compounds R2 Urease Inhibitory Activity Antiglycation Activity Cytotoxicity
IC50 ± SEMa IC50 ± SEMa IC50 ± SEMa
42 NAb 333.63 ± 1.98 >30
43 NAb NAb NTc
44 NAb NAb NTc
Standards Thiouread 21.3 ± 1.3
Rutine 294 ± 1.5 –
Cycloheximidef – 0.26 ± 0.1
SEMa (Standard error of mean); NAb (Not Active); NTc (Non Toxic); Thiouread (Standard inhibitor of urease inhibitory activity); Rutine (Standard inhibitor of
antiglycation activity); Cycloheximidef (Standard inhibitor for cytotoxicity).
Fig. 2. 1H- and 13C NMR chemical shifts of compound 21.
Fig. 3. General structural features of bis-coumarin.
4. Experimental
4.1. Materials and methods
Thin layer chromatography (TLC) was performed on pre-coated si-
lica gel aluminum plates (Kieselgel 60 F-254, 0.20mm, Merck,
Darmstadt, Germany). Chromatograms were visualized by using a
handhold UV lamp at 254, and 365 nm or placing in iodine vapors. Fast
atom bombardement mass spectra (FAB MS) were recorded on a
Finnigan MAT-311A (Germany) (70 eV) spectrometers, electrospray
ionization mass spectra (ESI-MS, HRESI-MS) were recorded on a QSTAR
XL LCMS-MS, and ABSciex (Germany) (50 kV) mass spectrometers, and
the data are tabulated as m/z. 1H - and 13C NMR spectroscopic analysis
was performed on an Avance Bruker (Germany) AM spectrometer
300MHz machine. Splitting patterns for 1H NMR spectra were as fol-
lows, s (singlet); d (doublet); t (triplet); m (multiplet). Chemical shifts
are reported in δ (ppm) and coupling constants are given in Hz. All
solvents and reagents were of reagent grade, and used directly without
purification. Melting points of the compounds were determined on
Büchi-M560 melting point apparatus.
4.2. General procedure for the syntheses of bis-coumarin derivatives 1–44
6-Fluoro-4-hydroxy /6-chloro-4-hydroxy /4-hydroxy coumarin
(1mmol), and a variety of aromatic aldehydes (0.5 mmol), as well as
10mol% of tetraethylammonium bromide (TEAB) were dissolved in
distilled water (15mL) in a 100mL round-bottommed flask. The reac-
tion mixture was refluxed for 2 h. Periodic TLC was taken to check the
progress of reaction. Resulting precipitates were filtered, and washed
with distilled water. This afforded products 1–44 in high yields.
4.3. 3,3′-((2′′,3′′-Dimethoxyphenyl)methylene)bis(6-fluoro-4-hydroxy-
2H-chromen-2-one) (1)
White Solid; Yield: 82%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
Acetone-d6): δ 11.25 (s, 2H, 2OH), 7.67 (d, J5,6/5′,6′ = 8.7 Hz, 2H, H-5,
H-5′), 7.50 (d, J7,8/7′,8′/8,7/8′,7′ = 5.4 Hz, 4H, H-7, H-8, H-7′, H-8′), 7.01
(m, 3H, H-4′′, H-5′', H-6′′), 6.22 (s, 1H, eCHe), 3.81 (s, 3H, OCH3a),
3.49 (s, 3H, OCH3b); 13C NMR (75MHz, DMSO-d6): δ165.8, 165.8,
163.8, 168.3, 159.3, 159.3, 156.1, 152.3, 148.5, 146.4, 136.0, 124.4,
122.3, 121.1, 121.0, 120.9, 118.1, 117.8, 117.5, 117.3, 110.5, 109.3,
108.9, 104.5, 59.3, 55.4, 32.7; FAB (Pos.)-MS m/z=509 [M+H]+;
ESI-MS m/z=509 [M+H]+; HRESI-MS Calcd for C27H19F2O8 [M
+H]+: m/z=509.1047, found 509.1090.
4.4. 3,3′-((2′′-Fluoro-4′′-methoxyphenyl)methylene)bis(6-fluoro-4-
hydroxy-2H-chromen-2-one) (2)
White Solid; Yield: 87%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 11.31 (bd.s, 2H, 2OH), 7.68 (d, J5,6F/5′,6F= 8.7 Hz, 2H, H-
Fig. 4. Structure-activity relationship of compounds 2, 3, 5, 8, 14, and 15.
Fig. 5. Structure-activity relationship of compounds 4, 9, and 10. 
5, H-5′), 7.52 (d, J8,7/8′,7′/6′′,5′′ = 5.4 Hz, 3H, H-8, H-8′, H-6′′), 7.32 (m,
1H, H-3′'), 6.75 (m, 3H, H-7, H-7′, H-5′′), 6.19 (bd.s, 1H, eCHe), 3.80
(s, 3H, OCH3); 13C NMR (75MHz, DMSO-d6): δ 160.2, 159.9, 159.9,
159.2, 159.2, 156.7, 149.7, 148.5, 129.1, 120.0, 119.7, 119.3, 118.7,
118.4, 117.4, 117.3, 114.9, 114.8, 113.6, 112.1, 109.5, 109.2, 108.5,
101.5, 55.5, 28.3; FAB (Neg.)-MS m/z=495 [M-H]−1; ESI-MS m/




White Solid; Yield: 79%; M.p.: 230–232 °C; 1H NMR (300MHz,
Acetone-d6): δ 11.47 (bd.s, 2H, 2OH), 7.68 (d, J5,6F/5′,6F= 8.1 Hz, 2H,
H-5, H-5′), 7.52 (bd.s, 5H, H-7, H-8, H-7′, H-8′, H-3′'), 7.32 (d,
J6′′,5′' = 8.1 Hz, 1H, H-6′'), 7.02 (d, J5′',6′' = 8.1 Hz, 1H, H-5′'), 6.15
(bd.s, 1H, eCHe), 3.86 (bd.s, 3H, OCH3); 13C NMR (75MHz, DMSO-
d6): δ 160.1, 160.1, 159.5, 159.5, 156.9, 149.9, 148.8, 129.2, 125.2,
120.0, 119.8, 119.4, 118.9, 118.6, 117.6, 117.4, 114.8, 114.6, 113.7,
112.3, 109.4, 109.2, 108.4, 101.6, 55.7, 28.5; FAB (Neg.)-MS m/
z=556 [M-H]−1, 558 [M+2-H]−1; ESI-MS m/z=557 [M+H]+, 559




White Solid; Yield: 81%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
Acetone-d6): δ 7.68 (dd, J5,7//5′,7′ = 2.1 Hz, J5,6F/5′,6F' = 7.8 Hz, 2H, H-
5, H-5′), 7.57 (d, J6′',5′' = 8.4 Hz, 1H, H-6′'), 7.49 (m, 4H, H-8, H-8′, H-
3′', H-5′'), 7.39 (dd, J7,5/7′,5′ = 2.1 Hz, J7,8/7′,8′ = 6.6 Hz, 2H, H-7, H-7′),
6.24 (s, 1H, eCHe); 13C NMR (75MHz, DMSO-d6): δ 160.4, 160.1,
159.3, 157.1, 156.5, 156.1, 148.2, 148.0, 141.5, 135.4, 132.5, 131.7,
130.0, 126.6, 125.0, 124.9, 119.1, 119.0, 115.2, 115.0, 111.4, 111.3,
100.2, 100.0, 28.2; FAB (Neg.)-MS m/z=516 [M-H]−1, 518 [M+2-
H]−1; ESI-MS m/z=517 [M+H]+; HRESI-MS Calcd for C25H13Cl2F2O6
[M+H]+: m/z=517.0057, Found 517.0071.
4.7. 3,3′-((5′′-Bromo-2′′-methoxyphenyl)methylene)bis(6-fluoro-4-
hydroxy-2H-chromen-2-one) (5)
White Solid; Yield: 77%; M.p.: 245–247 °C; 1H NMR (300MHz,
Acetone-d6): δ 11.21 (bd.s, 2H, 2OH), 7.67 (d, J5,6F/5′,6F' = 8.7 Hz, 2H,
H-5, H-5′), 7.51 (d, J8,7/8′,7′/6′',4′' = 5.7 Hz, 3H, H-8, H-8′, H-6′'), 7.43
(bd.s, 2H, H-7, H-7′), 6.96 (d, J3′′,4′′/4′',3′' = 8.7 Hz, 2H, H-3′', H-4′'), 6.14
(s, 1H, eCHe), 3.61 (s, 3H, OCH3a); 13C NMR (75MHz, DMSO-d6): δ
165.8, 165.8, 163.5, 159.3, 157.5, 156.5, 156.2, 148.5, 148.5, 133.1,
131.1, 129.2, 124.2, 120.8, 120.7, 118.3, 117.9, 117.6, 117.4, 113.2,
111.4, 109.3, 109.0, 103.7, 55.8, 32.9; FAB (Neg.)-MS m/z=556 [M-
H]−1, 558 [M+2-H]−1; ESI-MS m/z=557 [M+H]+, 559 [M+2+H]+;




White Solid; Yield: 76%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
Acetone-d6): δ 11.43 (s, 2H, 2OH), 7.68 (d, J5,6F/5′,6F= 8.7 Hz, 2H, H-5,
H-5′), 7.54 (d, J8,7/8′,7′/7,8= 5.7 Hz, 3H, H-7, H-8, H-8′), 7.21 (d, J2′′,3′′/
6′′,5′′/7′,8′ = 8.1 Hz, 3H, H-7′, H-2′', H-6′'), 7.14 (d, J3′′,2′′/5′′,6′′ = 8.1 Hz,
2H, H-3′', H-5′'), 6.10 (bd.s, 1H, eCHe), 2.29 (s, 3H, CH3); FAB (Neg.)-
MS m/z=461 [M-H]−1; ESI-MS m/z=463 [M+H]+; HRESI-MS
Calcd for C26H17F2O6 [M+H]+: m/z=463.0993, Found 463.1022.
4.9. 3,3′-((2′′,5′′-Dimethoxyphenyl)methylene)bis(6-fluoro-4-hydroxy-
2H-chromen-2-one) (7)
White Solid; Yield: 72%; M.p.: 240–242 °C; 1H NMR (300MHz,
Acetone-d6): δ 11.20 (s, 2H, 2OH), 7.67 (d, J5,6F/5′,6F= 8.7 Hz, 2H, H-5,
H-5′), 7.50 (d, J7,8/7′,8′/8,7/8′,7′ = 5.7 Hz, 4H, H-7, H-8, H-7′, H-8′), 6.91
(m, 3H, H-3′′, H-4′', H-6′'), 6.10 (s, 1H, eCHe), 3.68 (s, 3H, OCH3a),
3.52 (s, 3H, CH3b); 13C NMR (75MHz, DMSO-d6): δ 165.1, 165.1,
163.7, 163.7, 159.3, 159.3, 156.2, 152.6, 148.5, 146.3, 131.4, 125.3,
120.5, 120.4, 118.3, 118.0, 117.6, 117.5, 116.4, 111.9, 109.6, 109.3,
108.9, 104.4, 56.2, 55.0, 33.0; FAB (Neg.)-MS m/z=507 [M-H]−1;
ESI-MS m/z=509 [M+H]+; HRESI-MS Calcd for C27H19F2O8 [M
+H]+: m/z=509.1047, Found 509.1064.
Fig. 6. Structure-activity relationship of compounds 11–13.
Fig. 7. Structure-activity relationship of compounds 16, 17, and 20.
4.10. 3,3′-((3′′-(Benzyloxy)-4′′-methoxyphenyl)methylene)bis(6-fluoro-4-
hydroxy-2H-chromen-2-one) (8)
White Solid; Yield: 80%; M.p.: 200–202 °C; 1H NMR (300MHz,
Acetone-d6): δ 11.41 (s, 2H, 2OH), 7.66 (d, J5,6F/5′,6F= 8.4 Hz, 2H, H-5,
H-5′), 7.54 (bd.d, J8,7/8′,7′/7,8/7′,8′ = 5.4 Hz, 4H, H-7, H-8, H-7′, H-8′),
7.27 (m, 5H, Ar-H), 6.96 (bd.s, 1H, H-2′'), 6.93 (d, J5′′,6′' = 7.5 Hz, 1H,
H-5′′), 6.87 (d, J6′′,5′' = 8.0 Hz, 1H, H-6′′), 6.05 (s, 1H, eCHe), 4.97 (s,
2H, –CH2-), 3.80 (s, 3H, OCH3); 13C NMR (100MHz, DMSO-d6): δ
162.7, 162.7, 161.6, 161.6, 159.4, 159.4, 149.5, 148.2, 148.2, 146.9,
136.6, 135.4, 128.7, 128.7, 127.5, 127.2, 127.2, 125.3, 125.3, 122.0,
119.2, 119.2, 115.0, 115.0, 114.2, 112.4, 111.5, 111.5, 100.3, 100.3,
71.4, 56.2, 28.4; FAB (Neg.)-MS m/z=582 [M-H]−1; ESI-MS m/




White Solid; Yield: 84%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 7.53 (d, J5,6F/5′,6F= 8.4 Hz, 2H, H-5, H-5′), 7.49 (dd,
J3′',5′'/5′',3′' = 3.0 Hz, J3′',2′'/5′',6′' = 6.0 Hz, 2H, H-3′', H-5′'), 7.37 (m, 4H,
H-8, H-8′, H-2′', H-6′'), 7.29 (d, J7,8/7′,8′ = 8.4 Hz, 2H, H-7, H-7′), 6.29
(bd.s, 1H, eCHe); 13C NMR (100MHz, DMSO-d6): δ 162.8, 162.8,
161.4, 161.4, 159.6, 159.6, 148.0, 148.0, 147.6, 128.9, 128.9, 128.4,
125.3, 125.3, 125.1, 125.1, 124.3, 119.4, 119.4, 115.5, 115.5, 111.6,
111.6, 100.9, 100.9, 28.4; FAB (Neg.)-MS m/z=515 [M-H]−1; ESI-MS




White Solid; Yield: 77%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
Acetone-d6): δ 11.52 (bd.s, 2H, 2OH), 7.69 (m, 4H, H-5, H-8, H-5′, H-
8′), 7.55 (m, 6H, H-7, H-7′, H-2′', H-4′', H-5′', H-6′'), 6.30 (s, 1H, eCHe);
13C NMR (100MHz, DMSO-d6): δ 162.8, 162.8, 161.4, 161.4, 159.6,
159.6, 148.0, 148.0, 142.7, 131.2, 130.7, 128.7, 127.3, 125.3, 125.3,
124.5, 122.2, 119.4, 119.4, 115.5, 115.5, 111.6, 111.6, 100.9, 100.9,
28.5; FAB (Neg.)-MS m/z=515 [M-H]−1; ESI-MS m/z=517 [M




White Solid; Yield: 73%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 7.88 (m, 1H, H-5), 7.75 (m, 1H, H-5′), 7.61 (m, 2H, H-8, H-
8′), 7.46 (m, 3H, H-7, H-7′, H-6′'), 7.19 (m, 1H, H-4′'), 6.98 (m, 1H, H-
3′'), 5.69 (s, 1H, eCHe); 13C NMR (100MHz, DMSO-d6): δ 162.2,
161.9, 160.5, 160.1, 159.5, 159.0, 155.2, 151.6, 149.5, 148.8, 125.6,
125.1, 122.5, 119.9, 119.5, 117.6, 117.2, 117.0, 114.8, 114.7, 109.7,
109.4, 101.6, 101.4, 28.5; FAB (Neg.)-MS m/z=462 [M-H−HF]−1;
ESI-MS m/z=465 [M+H-H2O]+; HRESI-MS Calcd for C25H12F3O6 [M
+H-H2O]+: m/z=465.0585, Found 465.0549.
Fig. 8. Structure-activity relationship of compounds 19, 21, and 22.
Fig. 9. Structure-activity relationship of compounds 34, 35, 37, 40, 42, and 44.
6.76 (d, J4′',5′' = 7.5 Hz, 1H, H-4′'), 5.67 (s, 1H, eCHe); 13C NMR
(75MHz, DMSO-d6): δ 160.5, 152.1, 151.9, 151.9, 145.0, 145.0, 132.3,
132.3, 132.0, 132.0, 125.0, 124.3, 124.3, 123.9, 123.9, 123.2, 123.2,
118.2, 116.3, 116.3, 116.1, 116.1, 115.4, 114.0, 28.7; FAB (Neg.)-MS
m/z=425 [M-H-H2O]−1; ESI-MS m/z=427 [M+H-H2O]+; HRESI-




White Solid; Yield: 77%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
Acetone-d6): δ 8.36 (d, J5,6= 8.1 Hz, 1H, H-5), 8.36 (bd.s, 1H, OH),
8.08 (bd.s, 1H, OH), 8.05 (d, J5′,6′ = 6.6 Hz, 1H, H-5′), 7.72 (t,
J7,6= J7,8= 8.7 Hz, 1H, H-7), 7.60 (t, J7′,6′ = J7′,8′ = 7.2 Hz, 1H, H-7′),
7.49 (t, J6,5= J6,7= 7.2 Hz, 1H, H-6), 7.40 (d, J6′',5′' = 8.7 Hz, 1H, H-
6′'), 7.38 (t, J6′,5′ = J6′,7′ = 8.1 Hz, 1H, H-6′), 7.24 (d, J5′',6′' = 8.1 Hz,
1H, H-5′'), 6.66 (m, 2H, H-8, H-8′), 5.60 (s, 1H, eCHe); 13C NMR
(100MHz, DMSO-d6): δ 160.5, 160.5, 156.1, 152.0, 152.0, 151.8,
151.8, 145.5, 145.5, 138.7, 132.9, 132.9, 132.2, 131.9, 124.3, 124.3,
123.8, 123.4, 117.3, 116.2, 116.1, 114.1, 112.2, 28.3; FAB (Neg.)-MS
m/z=441 [M-H-H2O]−1; ESI-MS m/z=443 [M+H-H2O]+; HRESI-




White Solid; Yield: 73%; M.p.: 203–205 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.81 (d, J5,6/5′,6′ = 7.5 Hz, 2H, H-5, H-5′), 7.49 (t,
J7,6= J7,8= J7′,6′ = J7′,8′ = 6.9 Hz, 2H, H-7, H-7′), 7.24 (d, J8,7/
8′,7′ = 8.1 Hz, 2H, H-8, H-8′), 7.24 (t,
J6,5= J6,7= J6′,5′ = J6′,7′ = 8.1 Hz, 2H, H-6, H-6′), 7.14 (d,
J4′',5′' = 8.4 Hz, 1H, H-4′'), 6.80 (m, 2H, H-5′′, H-6′'), 6.02 (s, 1H,
eCHe), 2.16 (s, 3H, CH3), 2.01 (s, 1H, CH3); 13C NMR (100MHz,
DMSO-d6): δ 162.2, 162.2, 161.4, 161.4, 152.6, 152.6, 136.8, 135.7,
135.4, 128.2, 128.2, 127.5, 125.4, 125.3, 125.3, 123.4, 123.4, 121.4,
116.6, 116.6, 112.2, 112.2, 100.0, 100.0, 28.5, 19.3, 17.2; FAB (Neg.)-
MS m/z=439 [M-H]−1; ESI-MS m/z=441 [M+H]+; HRESI-MS
Calcd for C27H21O6 [M+H]+: m/z=441.1338, Found 441.1328.
4.21. 3,3′-((5′′-Chloro-2′′-hydroxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (19)
White Solid; Yield: 78%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 8.10 (d, J5,6= 7.5 Hz, 1H, H-5), 8.04 (bd.d, 1H, H-5′),
7.73 (t, J7,6= J7,8= 8.7 Hz, 1H, H-7), 7.62 (t, J7′,6′ = J7′,8′ = 8.4 Hz,
1H, H-7′), 7.51 (m, 6H, H-6, H-8, H-6′, H-8′, H-3′', H-4′'), 7.18 (s, 1H, H-
6′'), 5.70 (bd.s, 1H, eCHe); FAB (Neg.)-MS m/z=461 [M-H]−1, 463
[M+2-H]−1; ESI-MS m/z=445 [M+H-H2O]+; HRESI-MS Calcd for
C25H14ClO6 [M+H-H2O]+: m/z=445.0478, Found 445.0453.
4.22. 3,3′-((2′′,4′′-Dihydroxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (20)
White Solid; Yield: 82%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 9.68 (s, 1H, OH), 8.07 (d, J5,6= 6.9 Hz, 1H, H-5), 7.95
(bd.s, 1H, H-5′), 7.69 (t, J7,6= J7,8= 7.2 Hz, 1H, H-7), 7.52 (t,
J7′,6′ = J7′,8′ = 7.2 Hz, 1H, H-7′), 7.48 (t, J6,5= J6,7= 8.1 Hz, 1H, H-6),
7.43 (d, J8,7= 7.5 Hz, 1H, H-8), 7.25 (m, 2H, H-6′, H-8′), 7.00 (d,
J6′',5′' = 8.4 Hz, 1H, H-6′'), 6.67 (d, J3′',5′' = 2.1 Hz, 1H, H-3′'), 6.55 (dd,
J5′',3′' = 2.1 Hz, J5′',6′' = 6.0 Hz, 1H, H-5′'), 5.57 (s, 1H, eCHe); FAB
(Neg.)-MS m/z=425 [M-H-H2O]−1; ESI-MS m/z=427 [M+H-




White Solid; Yield: 79%; M.p.: > 300 °C dec.; 1H NMR (300 MHz, 
Acetone-d6): δ 7.84 (m, 2H, H-5, H-5′), 7.50 (m, 7H, H-7, H-8, H-7′, H-
8′, H-3′', H-4′', H-6′'), 5.79 (s, 1H, eCHe); 13C NMR (100 MHz, DMSO-
d6): δ 162.5, 162.2, 160.4, 160.0, 159.6, 159.3, 151.4, 149.5, 148.9, 
126.7, 125.7, 125.2, 122.6, 119.8, 119.4, 117.7, 117.4, 117.1, 114.7, 
114.3, 109.8, 109.3, 101.7, 101.5, 28.6; FAB (Neg.)-MS m/z = 497 [M-
H]−1; 499 [M+2-H]−1; ESI-MS m/z = 499 [M+H]+; HRESI-MS Calcd 
for C25H13ClF2O7 [M+H]+: m/z = 499.0318, Found 499.0336.
4.15 . 3,3′-((2′′,4′′-Dihydroxyphenyl)methylene)bis(6-fluoro-4-hydroxy-
2H-chromen-2-one) (13)
White Solid; Yield: 81%; M.p.: > 300 °C dec.; 1H NMR (300 MHz, 
Acetone-d6): δ 7.84 (dd, J5,7 = 2.1 Hz, J5,6F = 8.7 Hz, 1H, H-5), 7.76 (d, 
J5′,7′ = 2.4 Hz, J5′,6F = 8.7 Hz, 1H, H-5′), 7.52 (m, 4H, H-7, H-8, H-7′, 
H-8′), 7.10 (d, J6′',5′' = 8.4 Hz, 1H, H-6′'), 6.82 (bd.s, 1H, H-3′'), 6.65 (m, 
1H, H-5′'), 5.62 (bd.s, 1H, eCHe); 13C NMR (75 MHz, DMSO-d6): δ 
160.2, 159.9, 159.5, 157.3, 156.7, 156.3, 148.5, 148.3, 129.1, 119.9, 
119.6, 119.5, 119.2, 118.7, 118.6, 118.4, 118.3, 115.0, 114.9, 113.1, 
111.9, 108.6, 108.3, 102.9, 28.2; FAB (Neg.)-MS m/z = 461 [M-H-
H2O]−1; ESI-MS m/z = 463 [M+H-H2O]+; HRESI-MS Calcd for 
C25H13F2O7 [M+H-H2O]+: m/z = 463.0629, Found 463.0616.
4.16. 3,3′-((3′′-Bromo-4′′-methoxyphenyl)methylene)bis(6-fluoro-4-
hydroxy-2H-chromen-2-one) (14)
White Solid; Yield: 85%; M.p.: 210–212 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 11.47 (s, 2H, 2OH), 7.69 (d, J5,6F/5′,6F = 8.7 Hz, 2H, H-5, 
H-5′), 7.54 (d, J7,8/8,7/7′,8′/8′,7′ = 6.6 Hz, 4H, H-7, H-8, H-7′, H-8′), 7.52 
(bd.s, 1H, H-2′'), 7.32 (bd.d, J6′',5′' = 8.1 Hz, 1H, H-6′'), 7.02 (d, 
J5′',6′' = 8.4 Hz, 1H, H-5′'), 6.14 (s, 1H, eCHe), 3.87 (s, 3H, OCH3); 13C 
NMR (75 MHz, DMSO-d6): δ 166.5, 166.4, 164.1, 159.4, 156.2, 153.1, 
148.7, 135.4, 130.8, 127.2, 120.8, 120.7, 118.6, 118.2, 117.7, 117.6, 
112.3, 110.0, 109.4, 109.1, 103.7, 56.1, 35.2; FAB (Neg.)-MS m/
z = 555 [M-H]−1, 557 [M+2-H]−1; ESI-MS m/z = 557 [M+H]+; 




White Solid; Yield: 83%; M.p.: 205–207 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 11.30 (s, 2H, 2OH), 7.67 (d, J8,7/8′,7′ = 8.4 Hz, 2H, H-8, 
H-8′), 7.49 (d, J7,8/8,7/7′,8′/8′,7′ = 5.4 Hz, 4H, H-7, H-8, H-7′, H-8′), 7.14 
(s, 1H, H-3′'), 7.10 (s, 1H, H-6′'), 6.13 (s, 1H, eCHe), 3.72 (s, 3H, 
OCH3b), 3.57 (s, 3H, OCH3a); 13C NMR (75 MHz, DMSO-d6): δ 165.7, 
165.6, 163.6, 163.5, 159.3, 159.2, 151.8, 149.6, 148.8, 148.5, 131.3, 
125.3, 125.2, 120.8, 120.7, 118.3, 117.9, 117.6, 117.4, 116.0, 114.4, 
109.3, 109.0, 107.5, 104.0, 56.5, 56.5, 33.0; FAB (Neg.)-MS m/z = 586 
[M-H]−1, 588 [M+2-H]−1; ESI-MS m/z = 587 [M+H]+, 589 [M
+2+H]+; HRESI-MS Calcd for C27H18BrF2O8 [M+H]+: m/
z = 587.0153, Found 587.0111.
4.18. 3,3′-((2′′,3′′-Dihydroxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (16)
White Solid; Yield: 82%; M.p.: 110–112 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 8.64 (bd.s, 1H, OH), 8.36 (d, J5,6 = 8.1 Hz, 1H, H-5), 
8.06 (d, J5′,6′ = 8.1 Hz, 1H, H-5′), 7.72 (t, J7,6 = J7,8 = 8.4 Hz, 1H, H-
7), 7.61 (t, J7′,6′ = J7′,8′ = 7.2 Hz, 1H, H-7′), 7.49 (t, 
J6,5 = J6,7 = 7.2 Hz, 1H, H-6), 7.39 (d, J8,7 = 8.7 Hz, 1H, H-8), 7.39 (t, 
J6′,5′ = J6′,7′ = 8.7 Hz, 1H, H-6′), 7.24 (d, J8′,7′ = 8.1 Hz, 1H, H-8′), 6.98 
(t, J5′',4′' = J5′',6′' = 7.8 Hz, 1H, H-5′'), 6.88 (d, J6′',5′' = 6.6 Hz, 1H, H-6′'),
4.27. 3,3′-((4′′-Ethoxy-3′′-methoxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (25)
White Solid; Yield: 78%; M.p.: 195–197 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.81 (dd, J5,7/5′,7′ = 1.5 Hz, J5,6/5′,6′ = 6.3 Hz, 2H, H-5, H-
5′), 7.50 (t, J7,6= J7,8= J7′,6′ = J7′,8′ = 6.9 Hz, 2H, H-7, H-7′), 7.25 (d,
J8,7/8′,7′ = 8.1 Hz, 2H, H-8, H-8′), 7.23 (t, J6,7= J6,8= J6′,7′ = J6′,8′ =
7.2 Hz, 2H, H-6, H-6′), 6.73 (d, J5′',6′' = 8.7 Hz, 1H, H-5′'), 6.64 (s, 1H,
H-2′′), 6.60 (d, J6′',5′' = 8.7 Hz, 1H, H-6′'), 6.18 (s, 1H, eCHe), 3.92 (q,
2H, OCH2e), 3.50 (s, 3H, OCH3), 1.29 (t, 3H, CH3); FAB (Neg.)-MS m/
z=485 [M-H]−1; ESI-MS m/z=487 [M+H]+; HRESI-MS Calcd for
C28H23O8 [M+H]+: m/z=487.1392, Found 487.1385.
4.28. 3,3′-((2′′,4′′-Dimethoxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (26)
White Solid; Yield: 72%; M.p.: 197–199 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.82 (d, J5,6/5′,6′ = 6.9 Hz, 2H, H-5, H-5′), 7.50 (t,
J7,6= J7,8= J7′,6′ = J7′,8′ = 8.4 Hz, 2H, H-7, H-7′), 7.25 (d, J8,7/
8′,7′ = 8.1 Hz, 2H, H-8, H-8′),7.22 (t, J6,7= J6,8= J6′,7′ = J6′,8′ =
7.8 Hz, 2H, H-6, H-6′), 7.06 (d, J6′',5′' = 8.1 Hz, 1H, H-6′'), 6.39 (m, 2H,
H-3′', H-5′'), 6.12 (s, 1H, eCHe), 3.68 (s, 3H, OCH3b), 1.29 (t, 3H,
OCH3a); 13C NMR (100MHz, DMSO-d6): δ 164.4, 163.9, 158.8, 158.0,
152.0, 131.2, 131.2, 128.7, 123.6, 123.6, 123.3, 123.3, 120.9, 118.2,
115.7, 115.7, 104.6, 103.8, 98.5, 55.5, 55.0, 32.2; FAB (Neg.)-MS m/
z=470 [M-H]−1; ESI-MS m/z=473 [M+H]+; HRESI-MS Calcd for
C27H21O8 [M+H]+: m/z=473.1236, Found 473.1230.
4.29. 3,3′-((4′′-Bromo-2′′-fluorophenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (27)
White Solid; Yield: 83%; M.p.: 245–247 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.81 (d, J5,6/5′,6′ = 6.6 Hz, 2H, H-5, H-5′), 7.52 (t,
J7,6= J7,8= J7′,6′ = J7′,8′ = 8.4 Hz, 2H, H-7, H-7′), 7.27 (m, 7H, H-6, H-
8, H-6′, H-8′, H-3′', H-5′', H-6′′), 6.24 (s, 1H, eCHe); 13C NMR
(100MHz, DMSO-d6): δ 162.9, 162.5, 162.2, 160.4, 160.0, 151.4,
150.9, 132.6, 128.4, 127.2, 125.7, 125.2, 121.5, 120.5, 119.8, 119.4,
117.7, 117.4, 114.7, 114.3, 109.8, 109.3, 101.7, 101.5, 28.6; FAB
(Neg.)-MS m/z=507 [M-H]−1, 509 [M+2-H]−1; ESI-MS m/z=509
[M+H]+, 511 [M+2+H]+; HRESI-MS Calcd for C25H15BrFO6 [M
+H]+: m/z=509.0036, Found 509.0032.
4.30. 3,3′-((2′′-Bromo-4′′,5′′-dimethoxyphenyl)methylene)bis(4-hydroxy-
2H-chromen-2-one) (28)
White Solid; Yield: 85%; M.p.: 200–202 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.83 (d, J5,6/5′,6′ = 6.6 Hz, 2H, H-5, H-5′), 7.26 (t,
J7,6= J7,8= J7′,6′ = J7′,8′ = 7.2 Hz, 2H, H-7, H-7′), 7.26 (d, J8,7/
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.25 (t, J6,7= J6,8= J6′,7′ = J6′,8′ =
8.1 Hz, 2H, H-6, H-6′), 7.01 (s, 1H, H-3′'), 6.97 (s, 1H, H-6′'), 5.97 (s,
1H, eCHe), 3.70 (s, 3H, OCH3a), 1.29 (t, 3H, OCH3b); 13C NMR
(100MHz, DMSO-d6): δ 190.1, 165.3, 163.5, 152.2, 147.6, 147.1,
133.0, 131.2, 131.2, 123.7, 123.7, 123.3, 123.3, 118.4, 116.0, 115.7,
115.7, 114.4, 113.4, 110.5, 104.1, 55.7, 55.6, 37.9; FAB (Neg.)-MS m/
z=549 [M-H]−1, 551 [M+2-H]−1; ESI-MS m/z=551 [M+H]+, 553




White Solid; Yield: 81%; M.p.: 210–212 °C; 1H NMR (300MHz,
Acetone-d6): δ 11.44 (s, 1H, OH), 8.01 (d, J5,6/5′,6′ = 6.9 Hz, 2H, H-5, H-
5′), 7.74 (t, J7,6= J7,8= J7′,6′ = J7′,8′ = 7.2 Hz, 2H, H-7, H-7′), 7.48 (t,
J6,7= J6,8= J6′,7′ = J6′,8′ = 8.1 Hz, 2H, H-6, H-6′), 7.48 (d, J8,7/
8′,7′ = 7.8 Hz, 2H, H-8, H-8′), 7.26 (m, 2H, H-2′'', H-6′''), 7.20 (m, 3H, H-
4.23. 3,3′-((3′′,5′′-Dibromo-4-hydroxyphenyl)methylene)bis(4-hydroxy-
2H-chromen-2-one) (21)
White Solid; Yield: 87%; M.p.: > 300 °C dec.; 1H NMR (300 MHz, 
DMSO-d6): δ 7.82 (d, J5,6/5′,6′ = 6.3 Hz, 2H, H-5, H-5′), 7.53 (t, 
J7,6 = J7,8 = J7′,6′ = J7′,8′ = 6.9 Hz, 2H, H-7, H-7′), 7.27 (d, J8,7/ 
8′,7′ = 8.1 Hz, 2H, H-8, H-8′), 7.26 (t, J6,5 = J6,7 = J6′,5′ = J6′,7′ = 
7.5 Hz, 2H, H-6, H-6′), 7.12 (bd.s, 2H, H-2′', H-6′'), 6.16 (s, 1H, eCHe); 
13C NMR (75 MHz, DMSO-d6): δ 167.2, 167.2, 164.2, 164.2, 152.4, 
152.4, 148.1, 148.1, 136.6, 131.3, 131.3, 130.2, 130.2, 124.0, 124.0, 
123.1, 123.1, 119.3, 119.3, 115.6, 115.6, 111.7, 102.9, 102.9, 35.0; 
FAB (Neg.)-MS m/z = 584 [M-H],−1 586 [M+2-H]−1; ESI-MS m/
z = 585 [M+H],+ 587 [M+2+H],+ 589 [M+4+H]+; HRESI-MS 
Calcd for C25H15Br2O7 [M+H]+: m/z = 584.9184, Found 584.9208.
4.24. 3,3′-((3′′,5′′-Dichlorophenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (22)
White Solid; Yield: 82%; M.p.: 232–234 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 8.14 (d, J5,6 = 6.3 Hz, 1H, H-5), 8.08 (d, J5′,6′ = 6.6 Hz, 
1H, H-5′), 7.76 (t, J7,6 = J7,8 = 8.4 Hz, 1H, H-7), 7.62 (t, 
J7′,6′ = J7′,8′ = 7.5 Hz, 1H, H-7′), 7.55 (t, J6,5 = J6,7 = 7.5 Hz, 1H, H-6), 
7.52 (d, J2′',6′'/6′′,2′′ = 2.4 Hz, 1H, H-2′', H-6′′), 7.43 (t, 
J6′,5′ = J6′,7′ = 8.4 Hz, 1H, H-6′), 7.38 (d, J8,7 = 7.2 Hz, 1H, H-8), 7.32 
(d, J4′′,2′′/4′′,6′′ = 2.4 Hz, 1H, H-4′′), 7.27 (d, J8′,7′ = 8.1 Hz, 1H, H-8′), 
5.74 (s, 1H, eCHe); 13C NMR (100 MHz, DMSO-d6): δ 162.7, 162.7, 
161.6, 161.6, 152.4, 152.4, 145.2, 135.7, 135.7, 128.4, 128.4, 126.8, 
126.8, 126.3, 125.3, 125.3, 123.4, 123.4, 116.5, 116.5, 116.3, 116.3, 
100.1, 100.1, 28.4; FAB (Neg.)-MS m/z = 476 [M-H]−1, 478 [M+2-
H]−1; ESI-MS m/z = 479 [M+H]+, 481 [M+2+H]+; HRESI-MS Calcd 
for C25H15Cl2O6 [M+H]+: m/z = 479.0089, Found 479.0105.
4.25 . 3,3′-((2′′,5′′-Dimethoxyphenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (23)
White Solid; Yield: 74%; M.p.: 181–183 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.87 (dd, J5,7/5′,7′ = 1.2 Hz, J5,6/5′,6′ = 6.6 Hz, 2H, H-5, H-
5′), 7.56 (t, J7,6 = J7,8 = J7′,6′ = J7′,8′ = 8.4 Hz, 2H, H-7, H-7′), 7.31 (d, 
J8,7/8′,7′ = 7.8 Hz, 2H, H-8, H-8′), 7.30 (t, J6,7 = J6,8 = J6′,7′ = J6′,8′ = 
7.5 Hz, 2H, H-6, H-6′), 6.79 (d, J4′',3′' = 8.4 Hz, 1H, H-4′'), 6.71 (s, 1H, 
H-6′′), 6.71 (d, J3′',4′' = 8.7 Hz, 1H, H-3′'), 6.19 (s, 1H, eCHe), 3.60 (s, 
3H, OCH3a), 3.48 (s, 3H, OCH3b); 13C NMR (75 MHz, DMSO-d6): δ 
165.1, 163.9, 152.7, 152.1, 151.6, 131.1, 131.1, 123.7, 123.7, 123.2, 
123.2, 118.5, 116.2, 115.6, 115.6, 111.8, 109.6, 104.2, 56.1, 55.0, 
32.9; FAB (Neg.)-MS m/z = 470 [M-H]−1; ESI-MS m/z = 473 [M




White Solid; Yield: 76%; M.p.: 190–192 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.85 (dd, J5,7/5′,7′ = 1.2 Hz, J5,6/5′,6′ = 6.9 Hz, 2H, H-5, H-
5′),7.53 (t, J7,6 = J7,8 = J7′,6′ = J7′,8′ = 8.4 Hz, 2H, H-7, H-7′), 7.28 (d, 
J8,7/8′,7′ = 8.4 Hz, 2H, H-8, H-8′), 7.27 (t, J6,7 = J6,8 = J6′,7′ = J6′,8′ = 
7.5 Hz, 2H, H-6, H-6′), 6.89 (m, 3H, H-4′', H-5′', H-6′'), 6.29 (s, 1H, 
eCHe), 3.71 (s, 3H, OCH3b), 3.44 (s, 3H, OCH3a); 13C NMR (75 MHz, 
DMSO-d6): δ 165.0, 164.0, 152.2, 152.0, 146.5, 135.1, 131.2, 131.2, 
123.7, 123.7, 123.3, 123.3, 122.5, 120.8, 118.5, 115.7, 115.7, 110.7, 
104.6, 59.2, 55.4, 32.7; FAB (Neg.)-MS m/z = 471 [M-H+]−1. FAB 
(Neg.)-MS m/z = 471 [M-H]−1; ESI-MS m/z = 473 [M+H]+; HRESI-
MS Calcd for C27H21O8 [M+H]+: m/z = 473.1236, Found 473.1207.
4.36. 3,3′-((2′′,3′′,4′′-Trihydroxyphenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (34)
White Solid; Yield: 86%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 9.26 (bd.s, 1H, OH), 9.06 (bd.s, 1H, OH), 8.56 (d,
J5,7= 2.7 Hz, 2H, H-5), 7.95 (bd.s, 1H, H-5′), 7.72 (d, J7,8= 8.7 Hz,
1H, H-7), 7.58 (d, J7′,8′ = 9.0 Hz, 1H, H-7′), 7.47 (d, J8,7= 9.0 Hz, 1H,
H-8), 7.31 (d, J8′,7′ = 8.4 Hz, 1H, H-8′), 6.55 (d, J6′',5′' = 8.4 Hz, 1H, H-
6′'), 6.46 (d, J5′',6′' = 8.4 Hz, 1H, H-5′'), 5.56 (s, 1H, eCHe); 13C NMR
(100MHz, DMSO-d6): δ 166.0, 165.7, 164.1, 163.6, 151.4, 151.0,
148.6, 147.4, 133.9, 131.3, 130.9, 129.5, 129.2, 126.7, 126.4, 124.5,
122.9, 122.5, 118.9, 118.6, 116.7, 100.5, 100.2, 108.6, 30.6; FAB
(Neg.)-MS m/z=509 [M-H-H2O]−1; ESI-MS m/z=511 [M+H-




White Solid; Yield: 82%; M.p.:> 300 °C dec.; 1H NMR (300MHz,
DMSO-d6): δ 7.74 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.55 (dd, J7,5/
7′,5′ = 2.4 Hz, J7,8/7′,8′ = 6.3 Hz, 2H, H-7, H-7′), 7.32 (d, J8,7/
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.13 (s, 2H, H-2′', H-6′'), 6.13 (s, 1H,
eCHe); 13C NMR (100MHz, DMSO-d6): δ 166.4, 166.4, 164.3, 164.3,
151.3,150.8, 150.8, 139.0, 134.5, 134.5, 131.0, 131.0, 129.5, 129.5,
126.8, 126.8, 122.9, 122.9, 118.8, 118.8, 110.3, 110.3, 100.2, 100.2,
35.2; FAB (Neg.)-MS m/z=651 [M-H]−1; 653 [M+2-H]−1; ESI-MS m/




White Solid; Yield: 86%; M.p.: 252–254 °C; 1H NMR (300MHz,
DMSO-d6): δ 10.83 (s, 2H, 2OH), 9.13 (s, 1H, OH), 8.66 (d, J5′′,6′′/
8′',7′' = 8.4 Hz, 2H, H-5′′, H-8′'), 8.32 (d, J4′',3′' = 9.3 Hz, 1H, H-4′'), 8.11
(d, J3′',4′' = 7.8 Hz, 1H, H-3′'), 7.79 (t, J6′',5′' = J6′',7′' = 7.5 Hz, 1H, H-6′'),
7.67 (m, 4H, eCHe, H-5, H-5′, H-7′′), 7.51 (dd, J7,5/7′,5′ = 2.4 Hz, J7,8/
7′,8′ = 8.7 Hz, 2H, H-7, H-7′), 6.94 (d, J8,7/8′,7′ = 8.7 Hz, 2H, H-8, H-8′);
13C NMR (75MHz, DMSO-d6): δ 190.4, 158.1, 156.9, 154.3, 139.6,
139.6, 135.1, 135.1, 134.2, 134.2, 129.9, 129.4, 129.4, 129.2, 129.0,
129.0, 128.8, 128.8, 127.5, 126.4, 125.7, 122.9, 122.5, 122.5, 118.9,
118.9, 116.5, 112.7, 28.6; FAB (Neg.)-MS m/z=440 [M-
H−2H2O−2Cl]−1; ESI-MS m/z=529 [M+H-H2O]+; HRESI-MS Calcd
for C29H16Cl2O7 [M+H-H2O]+: m/z=529.0245, Found 529.0268.
4.39. 3,3′-((4′′-Hydroxy-3′′-iodo-5′′-methoxyphenyl)methylene)bis(6-
chloro-4-hydroxy-2H-chromen-2-one) (37)
White Solid; Yield: 80%; M.p.: 234–236 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.74 (d, J5,7/5′,7′ = 2.7 Hz, 2H, H-5, H-5′), 7.54 (dd, J7,5/
7′,5′ = 2.7 Hz, J7,8/7′,8′ = 6.3 Hz, 2H, H-7, H-7′), 7.31 (d, J8,7/
8′,7′ = 9.0 Hz, 2H, H-8, H-8′), 6.90 (bd.s, 1H, H-2′'), 6.64 (bd.s, 1H, H-
6′'), 6.12 (s, 1H, eCHe), 3.57 (s, 3H, OCH3); 13C NMR (75MHz, DMSO-
d6): δ 166.1, 166.1, 163.8, 163.8, 150.9, 150.9, 146.7, 143.9, 134.4,
130.7, 130.7, 127.8, 127.8, 127.2, 127.2, 123.1, 123.1, 121.0, 117.7,
117.7, 111.2, 104.0, 104.0, 84.1, 55.9, 35.4; FAB (Neg.)-MS m/z=651
[M-H]−1, 653 [M+2-H]−1; ESI-MS m/z=653 [M+H]+; HRESI-MS
Calcd for C26H16Cl2IO8 [M+H]+: m/z=652.9267, Found 652.9280.
4.40. 3,3′-((5′′-Bromo-2′′-methoxyphenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (38)
White Solid; Yield: 81%; M.p.: 251–253 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.73 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.52 (dd, J7,5/
7′,5′ = 2.7 Hz, J7,8/7′,8′ = 6.0 Hz, 2H, H-7, H-7′), 7.29 (d, J8,7/
3′'', H-4′'', H-6′''), 6.97 (bd.s, 1H, H-2′''), 6.93 (d, J6′',5′' = 7.2 Hz, 1H, H-
6′'), 6.87 (d, J5′',6′' = 7.2 Hz, 1H, H-5′'), 6.04 (s, 1H, eCHe), 4.96 (s, 2H, 
eCHe), 3.80 (s, 3H, OCH3); 13C NMR (100 MHz, DMSO-d6): δ 162.9, 
162.9, 161.7, 161.7, 152.6, 152.6, 149.8, 146.6, 136.5, 135.7, 128.7, 
128.7, 128.4, 128.4, 127.4, 127.2, 127.2, 125.5, 125.5, 123.2, 123.2, 
122.4, 116.7, 116.7, 116.2, 116.2, 114.2, 112.4, 100.4, 100.4, 71.2, 
28.7, 56.2; FAB (Neg.)-MS m/z = 546 [M-H]−1; ESI-MS m/z = 549 [M




White Solid; Yield: 84%; M.p.: 255–257 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 11.45 (s, 2H, 2OH), 8.02 (d, J5,6/5′,6′ = 7.2 Hz, 2H, H-5, 
H-5′), 7.75 (t, J7,6 = J7,8 = J7′,6′ = J7′,8′ = 7.5 Hz, 2H, H-7, H-7′), 7.51 
(m, 4H, H-6, H-8, H-6′, H-8′), 6.95 (s, 1H, H-2′'), 6.77 (s, 2H, H-5′', H-
6′'), 6.08 (s, 1H, eCHe), 3.67 (s, 3H, OCH3); FAB (Neg.)-MS m/z = 457 
[M-H]−1; ESI-MS m/z = 459 [M+H]+; HRESI-MS Calcd for C26H19O8 
[M+H]+: m/z = 459.1079, Found 459.1053.
4.33. 3,3′-((4′′-(Methylthio)phenyl)methylene)bis(4-hydroxy-2H-
chromen-2-one) (31)
White Solid; Yield: 77%; M.p.: 260–262 °C; 1H NMR (300 MHz, 
Acetone-d6): δ 11.50 (s, 2H, 2OH), 8.03 (d, J5,6/5′,6′ = 8.4 Hz, 2H, H-5, 
H-5′), 7.76 (t, J7,6 = J7,8 = J7′,6′ = J7′,8′ = 6.9 Hz, 2H, H-7, H-7′), 7.49 
(m, 4H, H-6, H-8, H-6′, H-8′), 7.29 (d, J2′',3′'/6′',5′' = 8.1 Hz, 2H, H-2′', H-
6′'), 7.23 (d, J3′',2′'/5′',6′' = 8.7 Hz, 2H, H-3′', H-5′'), 6.10 (s, 1H, eCHe), 
2.46 (s, 3H, SCH3); FAB (Neg.)-MS m/z = 457 [M-H]−1; ESI-MS m/
z = 459 [M+H]+; HRESI-MS Calcd for C26H19O6S [M+H]+: m/
z = 459.0902, Found 459.0922.
4.34. 3,3′-((3′′-Bromo-4′′-methoxyphenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (32)
White Solid; Yield: 85%; M.p.: 204–206 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.73 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.55 (dd, J7,5/ 
7′,5′ = 2.4 Hz, J7,8/7′,8′ = 9.0 Hz, 2H, H-7, H-7′), 7.32 (d, J8,7/ 
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.15 (bd.s, 1H, H-2′'), 7.04 (bd.d, 
J6′',5′' = 8.4 Hz, 1H, H-6′'), 6.92 (d, J5′',6′' = 8.7 Hz, 1H, H-5′'), 6.15 (s, 
1H, eCHe), 3.76 (s, 3H, OCH3); 13C NMR (100 MHz, DMSO-d6): δ 
166.3, 163.9, 153.1, 151.0, 135.3, 130.8, 130.8, 130.7, 127.2, 127.2, 
123.2, 123.2, 121.1, 117.7, 117.7, 112.3, 110.0, 103.8, 56.0, 32.2; FAB 
(Neg.)-MS m/z = 587 [M-H]−1; 589 [M+2-H]−1; 591 [M + 4-H]−1; 
ESI-MS m/z = 599 [M+H]+; HRESI-MS Calcd for C26H15BrCl2O7 [M
+H]+: m/z = 588.9456, Found 588.9479.
4.35 . 3,3′-((3′′-(Benzyloxy)phenyl)methylene)bis(6-chloro-4-hydroxy-
2H-chromen-2-one) (33)
White Solid; Yield: 80%; M.p.: 192–194 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.72 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.54 (dd, J7,5/ 
7′,5′ = 2.4 Hz, J7,8/7′,8′ = 6.3 Hz, 2H, H-7, H-7′), 7.31 (m, 4H, H-8, H-8′, 
H-3′'', H-5′''), 7.24 (m, 3H, H-2′'', H-4′'', H-6′''), 7.09 (t, 
J5′',4′' = J5′',6′' = 8.1 Hz, 1H, H-5′'), 6.74 (d, J6′',5′' = 8.1 Hz, 1H, H-6′'), 
6.64 (m, 2H, H-2′', H-4′'), 6.18 (s, 1H, eCHe), 4.94 (s, 3H, OCH2); 13C 
NMR (75 MHz, DMSO-d6): δ 166.1, 166.1, 164.0, 164.0, 158.3, 151.0, 
151.0, 143.2, 137.2, 130.8, 130.8, 128.8, 128.2, 128.2, 127.7, 127.6, 
127.6, 127.2, 127.2, 123.2, 123.2, 121.1, 119.3, 119.3, 117.7, 117.7, 
113.7, 110.9, 104.0, 104.0, 69.1, 36.2; FAB (Neg.)-MS m/z = 585 [M-
H]−1, 587 [M+2-H]−1; ESI-MS m/z = 587 [M+H]+; HRESI-MS Calcd 
for C32H21Cl2O7 [M+H]+: m/z = 587.0664, Found 587.0666.
H]−1, 619 [M+2-H]−1, 621 [M+4-H]−1; ESI-MS m/z=619 [M




White Solid; Yield: 75%; M.p.: 243–245 °C; 1H NMR (300MHz,
DMSO-d6): δ 8.13 (d, J5,7= 2.4 Hz, 1H, H-5), 7.99 (bd.s, 1H, H-5′), 7.74
(dd, J7,5= 2.8 Hz, J7,8= 6.0 Hz, 1H, H-7), 7.60 (bd.d, J7′,8′ = 7.2 Hz,
1H, H-7′), 7.50 (d, J8,7= 8.8 Hz, 1H, H-8), 7.33 (d, J8′,7′ = 9.2 Hz, 1H,
H-8′), 7.08 (d, J6′',5′' = 8.4 Hz, 1H, H-6′'), 7.03 (d, J3′',5′' = 2.4 Hz, 1H, H-
3′'), 6.73 (dd, J5′',3′' = 2.4 Hz, J5′',6′' = 6.3 Hz, 1H, H-5′'), 5.61 (bd.s, 1H,
eCHe), 3.77 (s, 1H, OCH3); 13C NMR (75MHz, DMSO-d6): δ 166.0,
166.0, 163.8, 163.8, 155.9, 151.0, 151.0, 143.0, 131.2, 131.2, 130.8,
130.8, 127.2, 127.2, 123.1, 123.1, 120.8, 118.3, 117.8, 117.8, 104.0,
104.0, 103.9, 96.7, 56.0, 36.7; FAB (Neg.)-MSm/z=527 [M-H]−1, 529
[M+2-H]−1; ESI-MS m/z=529 [M+H]+; HRESI-MS Calcd for
C26H15Cl2FO7 [M+H]+: m/z=529.0257, Found 529.0257.
4.46. 3,3′-((3′′-Bromo-4′′-hydroxy-5′′-methoxyphenyl)methylene)bis(6-
chloro-4-hydroxy-2H-chromen-2-one) (44)
White Solid; Yield: 87%; M.p.: 282–284 °C; 1H NMR (300MHz,
DMSO-d6): δ 7.74 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.54 (dd, J7,5/
7′,5′ = 2.4 Hz, J7,8/7′,8′ = 6.3 Hz, 2H, H-7, H-7′), 7.31 (d, J8,7/
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 6.70 (bd.s, 1H, H-6′'), 6.62 (bd.s, 1H, H-
2′'), 6.13 (s, 1H, eCHe), 3.58 (s, 3H, OCH3); 13C NMR (100MHz,
DMSO-d6): δ 166.1, 166.1, 163.8, 163.8, 150.9, 150.9, 148.1, 141.4,
133.4, 130.7, 130.7, 127.2, 127.2, 123.1, 123.1, 122.1, 121.0, 121.0,
117.7, 117.7, 110.2, 108.8, 103.9, 103.9, 56.0, 35.6; FAB (Neg.)-MS m/
z=604 [M-H]−1, 606 [M+2-H]−1; ESI-MS m/z=604 [M+H]+, 606
[M+2+H]+ 608 [M+4+H]+; HRESI-MS Calcd for C26H16BrCl2O8 [M
+H]+: m/z=604.9405, Found 604.9448.
4.47. Urease inhibitory assay
Urease (EC 3.5.1.5) enzyme solution (25 µL) and 55 µL buffers,
containing 100mM urea, were incubated at 30 °C for 15min along with
5 µL (1mM concentration) test compounds in 96-well plates. Ammonia
production was measured in order to determine urease activity by
utilizing the indophenols method by Weatherburn [25]. Briefly, 45 µL
phenol reagent (1% w/v phenol and 0.005% w/v sodium nitroprusside)
and 70 µL alkali reagent (0.5% w/v NaOH and 0.1% active chloride
NaOCl) were added to each well. By using a microplate reader (Spectra
Max, Molecular Devices, USA), increase in absorbance was recorded at
630 nm after 50min. All reactions were carried out thrice in a final
volume of 200 µL. The change in absorbance per min was processed by
serving SoftMax Pro software (Molecular Devices, USA). All the assays
were carried out at pH 8.2 (0.01M K2HPO4·3H2O, 1mM EDTA and
0.01M LiCl). Thiourea was used as the standard inhibitor of urease.
Percentage inhibitions were calculated from the following formula:
100 (OD /OD )x100testwell control
4.48. In vitro BSA-MG Anti-glycation assay
In this assay, BSA (Bovine serum albumin) of concentration (10mg/
mL) and (14mM) methylglyoxal were prepared in phosphate buffer
0.1M of pH 7.4, containing 3mM sodium azide (NaN3) which was used
as antimicrobial agent. 1 mM test compounds were dissolved in the
DMSO. Assay was performed in triplicate. Reaction mixtures contained
50 µL BSA, 50 µL methylglyoxal, 20 µL test compound, and 80 µL
phosphate buffer of pH 7.4. The reaction mixture was incubated for
9 days at 37 °C under aseptic conditions. Fluorescence was recorded for
excitation and emission at 330, and 420 nm on a microtitre plate reader
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.23 (d, J3′',4′' = 6.9 Hz, 1H, H-3′'), 7.21 (s, 
1H, H-6′'), 6.80 (d, J4′',3′' = 8.4 Hz, 1H, H-4′'), 6.15 (s, 1H, eCHe), 3.53 
(s, 1H, OCH3); 13C NMR (100 MHz, DMSO-d6): δ 166.2, 166.0, 163.7, 
163.5, 157.7, 150.7, 150.5, 134.6, 131.2, 131.0, 129.8, 129.6, 126.7, 
126.5, 129.4, 118.8, 118.6, 115.5, 113.6, 100.3, 100.1, 123.4, 122.8, 
122.6, 56.2, 29.7; FAB (Neg.)-MS m/z = 587 [M-H]−1, 589 [M+2-
H]−1, 591 [M + 4-H]−1; ESI-MS m/z = 599 [M+H]+; HRESI-MS 
Calcd for C26H15BrCl2O7 [M+H]+: m/z = 588.9456, Found 588.9478.
4.41. 3,3′-((2′′,5′′-Dihydroxyphenyl)methylene)bis(6-chloro-4-hydroxy-
2H-chromen-2-one) (39)
White Solid; Yield: 76%; M.p.: 274–276 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 9.37 (s, 1H, OH), 8.07 (d, J5,7 = 2.1 Hz, 1H, H-5), 8.00 
(bd.s, 1H, H-5′), 7.74 (dd, J7,5 = 2.4 Hz, J7,8 = 6.3 Hz, 1H, H-7), 7.62 
(d, J7′,8′ = 7.5 Hz, 1H, H-7′), 7.49 (d, J8,7 = 8.7 Hz, 1H, H-8), 7.35 (d, 
J8′,7′ = 8.7 Hz, 1H, H-8′), 7.21 (d, J3′',4′' = 8.7 Hz, 1H, H-3′'), 6.67 (d, 
J4′',3′' = 6.0 Hz, 1H, H-4′'), 6.58 (bd.s, 1H, H-6′'), 5.62 (bd.s, 1H, 
eCHe); 13C NMR (100 MHz, DMSO-d6): δ 166.2, 165.9, 164.3, 164.0, 
151.3, 151.0, 149.2, 148.7, 131.4, 131.1, 129.3, 129.0, 126.5, 126.2, 
124.3, 122.7, 122.5, 118.7, 118.4, 117.2, 116.7, 114.6, 104.6, 104.3, 
30.1; FAB (Neg.)-MS m/z = 493 [M-H-H2O]−1; 495 [M+2-H]−1; ESI-
MS m/z = 495 [M+H]+; HRESI-MS Calcd for C25H14Cl2O8 [M+H]+: 
m/z = 495.0038, Found 495.0065.
4.42. 3,3′-((3′′-Bromo-4′′-hydroxyphenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (40)
White Solid; Yield: 75%; M.p.: 248–250 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 9.84 (bd.s, 2H, 2OH),7.73 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, 
H-5′), 7.55 (dd, J7,5/7′,5′ = 2.7 Hz, J7,8/7′,8′ = 6.0 Hz, 2H, H-7, H-7′), 
7.31 (d, J8,7/8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.06 (bd.s, 1H, H-2′'), 6.88 (d, 
J6′',5′' = 8.7 Hz, 1H, H-6′'), 6.76 (d, J5′',6′' = 8.4 Hz, 1H, H-5′'), 6.11 (s, 
1H, eCHe); 13C NMR (100 MHz, DMSO-d6): δ 166.1, 166.1, 163.9, 
163.9, 151.5, 151.5, 151.0, 133.5, 133.5, 130.8, 130.5, 127.2, 127.2, 
127.1, 123.2, 123.2, 121.0, 121.0, 117.7, 117.7, 116.0, 108.7, 103.9, 
103.9, 35.2; FAB (Neg.)-MS m/z = 573 [M-H]−1, 575 [M+2-H]−1; 
ESI-MS m/z = 575 [M+H]+; HRESI-MS Calcd for C25H13BrCl2O7 [M
+H]+: m/z = 574.9300, Found 574.9326.
4.43. 3,3′-((2′′-Bromo-5′′-fluorophenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (41)
White Solid; Yield: 79%; M.p.: 273–275 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.74 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.55 (dd, J7,5/ 
7′,5′ = 2.7 Hz, J7,8/7′,8′ = 6.0 Hz, 2H, H-7, H-7′), 7.49 (m, 1H, H-3′'), 
7.31 (d, J8,7/8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 7.11 (dd, J6′′,4′′' = 3.0 Hz, 
J6′',F = 7.8 Hz, 1H, H-6′'), 6.99 (m, 1H, H-4′'), 5.97 (s, 1H, eCHe); 13C 
NMR (100 MHz, DMSO-d6): δ 166.0, 166.0, 163.4, 163.4, 161.6, 150.9, 
150.9, 142.4, 133.2, 131.4, 131.4, 129.7, 129.7, 126.8, 126.8, 122.7, 
122.7, 119.3, 118.7, 118.7, 118.6, 114.5, 104.2, 104.2, 31.8; FAB 
(Neg.)-MS m/z = 574 [M-H]−1, 576 [M+2-H]−1, 578 [M + 4-H]−1; 
ESI-MS m/z = 579 [M+H]+; HRESI-MS Calcd for C25H13BrCl2FO6 [M
+H]+: m/z = 576.9256, Found 576.9296.
4.44. 3,3′-((4′′-Bromo-3′′,5′′-dimethoxyphenyl)methylene)bis(6-chloro-4-
hydroxy-2H-chromen-2-one) (42)
White Solid; Yield: 82%; M.p.: 276–278 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 7.74 (d, J5,7/5′,7′ = 2.4 Hz, 2H, H-5, H-5′), 7.54 (dd, J7,5/ 
7′,5′ = 2.7 Hz, J7,8/7′,8′ = 6.3 Hz, 2H, H-7, H-7′), 7.31 (d, J8,7/ 
8′,7′ = 8.7 Hz, 2H, H-8, H-8′), 6.45 (s, 2H, H-2′', H-6′'), 6.19 (s, 1H, 
eCHe), 3.58 (s, 6H, 2OCH3); 13C NMR (100 MHz, DMSO-d6): δ 160.0, 
160.0, 159.2, 159.2, 155.2, 155.2, 150.6, 150.6, 149.7, 132.2, 132.2, 
131.8, 131.8, 129.1, 129.1, 128.7, 128.0, 118.6, 118.6, 117.7, 117.7, 
112.2, 112.2, 101.5, 55.5, 55.5, 28.2; FAB (Neg.)-MS m/z = 617 [M-
= (1 Fluorescence of test sample/Fluorescence of the control)x100
The IC50 values were determined at different concentrations
(1000–50 µM) of test compounds with the help of EZ-FIT Enzyme
Kinetics Program (Perrella Scientific Inc., Amherst, USA). Rutin was
used as a standard. In protein model system (BSA-MG glycation model),
it showed an IC50 of 294 ± 1.5 µM.
4.49. 3T3 cell based (mouse Fibroblast) cytotoxicity assay
Standard MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-dimethylte-
trazolium bromide) colorimetric assay was used to evaluate the cyto-
toxicity of thirteen bis-coumarin derivatives with antiglycation prop-
erties in 96-well flat-bottomed microplates. 3 T3 Cells (mouse
fibroblasts) in Dulbecco’s modified eagle’s medium was cultured for this
purpose, supplemented with streptomycin, penicillin, and 5% fetal
bovine serum (FBS) by using a flask placed in a 5% CO2 incubator at 37
⁰C. The growth of cells was harvested exponentially by using hemo-
cytometer, the harvested cells was counted and in a particular medium
was diluted. Cell cultures was prepared with a required concentration
and plated onto 96-well plates. After overnight incubation, medium was
removed and fresh medium was added with different concentrations of
the compound. After 72 h, MTT was added to each well, and incubation
was continued for 4 h. Subsequently, 100 µL of DMSO was added to
each well to solubilize formazan-MTT adduct, formed by the action of
enzyme mitochondrial dehydrogenase. The extent of MTT reduction to
formazan within cells was calculated by measuring the absorbance at
540 nm by using a microplate ELISA reader [32].
4.50. Statistical analysis
All experiments were conducted using (SpectraMax M5, molecular
Devices, CA. USA). Different softweres were used to analyze the results
i.e (MS-Excel, SoftMaxPro 4.8, and GraphPad Prism-6.0). In the end
IC50 values of active compounds were examined by using EZ-FIT,
Enzyme kinetics software (Perrella Scientific, Inc., USA)
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